{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:05Z","timestamp":1793973545005,"version":"4.8.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1G1A1003314"],"award-info":[{"award-number":["NRF-2021R1G1A1003314"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Hypofractionated radiotherapy has recently been applied to treat pulmonary metastases of hepatocellular carcinoma. However, there is no definite evidence on its safety and efficacy. We evaluate the clinical outcomes of hypofractionated radiotherapy for oligo pulmonary metastases of hepatocellular carcinoma in the multicenter and retrospective study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From March 2011 to February 2018, 58 patients with fewer than five pulmonary metastases of hepatocellular carcinoma who underwent hypofractionated radiotherapy in nine tertiary university hospitals were analyzed retrospectively. The primary endpoint was the local control rate. The secondary endpoints were overall survival, progression-free survival, prognostic factors affecting the treatment outcomes and treatment-related side effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The local tumor response rate including complete and partial response was 77.6% at 3\u00a0months after hypofractionated radiotherapy. The median survival and progression-free survival times were 20.9 and 5.3\u00a0months, respectively. The 1-year overall survival and progression-free survival rates were 65.5 and 22.4%, respectively. The good treatment response after hypofractionated radiotherapy (P\u00a0=\u00a00.001), the absence of intrahepatic tumor (P\u00a0=\u00a00.004) and Child-Pugh class A (P\u00a0=\u00a00.010) were revealed as significant prognostic factors for overall survival in the multivariate analysis. A progression-free interval of &amp;lt;6\u00a0months (P\u00a0=\u00a00.009) was a negative prognostic factor for overall survival in the multivariate analysis. Of 58 patients, five (8.6%) had grade 2 or higher radiation pneumonitis after hypofractionated radiotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The favorable local control rate and acceptable toxicity indicate the clinical usefulness of hypofractionated radiotherapy for hepatocellular carcinoma patients who have less than five pulmonary metastases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyac028","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T12:19:59Z","timestamp":1647865199000},"page":"616-622","source":"Crossref","is-referenced-by-count":23,"title":["Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08)"],"prefix":"10.1093","volume":"52","author":[{"given":"In Young","family":"Jo","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology , , Cheonan , Republic of Korea"},{"name":"Soonchunhyang University Hospital , , Cheonan , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Chul","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , Samsung Medical Center, , Seoul , Republic of Korea"},{"name":"Sungkyunkwan University School of Medicine , Samsung Medical Center, , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , , Cheonan , Republic of Korea"},{"name":"Soonchunhyang University Hospital , , Cheonan , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Gu","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , , Bucheon , Republic of Korea"},{"name":"Soonchunhyang University Hospital , , Bucheon , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myungsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, St. Mary Hospital , Incheon , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsil","family":"Seong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , , Seoul , Republic of Korea"},{"name":"Yonsei University College of Medicine , , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , , Seoul , Republic of Korea"},{"name":"Yonsei University College of Medicine , , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Research Institute and Hospital , National Cancer Center, Goyang , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sup","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , , Ansan , Republic of Korea"},{"name":"Korea University College of Medicine , , Ansan , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bae Kwon","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , , Jinju , Republic of Korea"},{"name":"Gyeongsang National University School of medicine and Gyeongsang National University Hospital , , Jinju , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , St. Vincent\u2019s Hospital, , Seoul , Republic of Korea"},{"name":"The Catholic University of Korea , St. Vincent\u2019s Hospital, , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3799-3312","authenticated-orcid":false,"given":"Jong Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , St. Vincent\u2019s Hospital, , Seoul , Republic of Korea"},{"name":"The Catholic University of Korea , St. Vincent\u2019s Hospital, , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"2022060109133260000_ref1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"2022060109133260000_ref2","first-page":"251","article-title":"Prognosis of hepatocellular carcinoma patients with extrahepatic metastases","volume":"44","author":"Okusaka","year":"1997","journal-title":"Hepatogastroenterology"},{"key":"2022060109133260000_ref3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.4143\/crt.2018.687","article-title":"Treatment outcome after fractionated conformal radiotherapy for hepatocellular carcinoma in patients with Child-Pugh classification B in Korea (KROG 16-05)","volume":"51","author":"Bae","year":"2019","journal-title":"Cancer Res Treat"},{"key":"2022060109133260000_ref4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2014.12.009","article-title":"Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors","volume":"62","author":"Sohn","year":"2015","journal-title":"J Hepatol"},{"key":"2022060109133260000_ref5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3748\/wjg.v13.i3.414","article-title":"Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma","volume":"13","author":"Uka","year":"2007","journal-title":"World J Gastroenterol"},{"key":"2022060109133260000_ref6","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.7150\/jca.19056","article-title":"Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study","volume":"8","author":"Wu","year":"2017","journal-title":"J Cancer"},{"key":"2022060109133260000_ref7","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s10620-019-05582-x","article-title":"Systemic management for advanced hepatocellular carcinoma: a review of the molecular pathways of carcinogenesis, current and emerging therapies, and novel treatment strategies","volume":"64","author":"Saffo","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2022060109133260000_ref8","doi-asserted-by":"crossref","first-page":"1073274817729243","DOI":"10.1177\/1073274817729243","article-title":"Role of systemic therapy and future directions for hepatocellular carcinoma","volume":"24","author":"Eatrides","year":"2017","journal-title":"Cancer Control"},{"key":"2022060109133260000_ref9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","article-title":"Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response","volume":"115","author":"Yau","year":"2009","journal-title":"Cancer"},{"key":"2022060109133260000_ref10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"2022060109133260000_ref11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14740330903510608","article-title":"Toxicity of sorafenib: clinical and molecular aspects","volume":"9","author":"Blanchet","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"2022060109133260000_ref12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2015-0478","article-title":"Sorafenib effectiveness in advanced hepatocellular carcinoma","volume":"21","author":"Sanoff","year":"2016","journal-title":"Oncologist"},{"key":"2022060109133260000_ref13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060109133260000_ref14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.lungcan.2010.02.014","article-title":"Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma","volume":"70","author":"Han","year":"2010","journal-title":"Lung Cancer"},{"key":"2022060109133260000_ref15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejcts.2008.03.056","article-title":"Surgical outcomes for pulmonary metastases from hepatocellular carcinoma","volume":"34","author":"Kawamura","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"2022060109133260000_ref16","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3 Suppl","key":"2022060109133260000_ref17","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022060109133260000_ref18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijrobp.2012.03.041","article-title":"Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung","volume":"85","author":"Baker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022060109133260000_ref19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2022060109133260000_ref20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1148\/radiol.2301021226","article-title":"Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance","volume":"230","author":"Aoki","year":"2004","journal-title":"Radiology"},{"key":"2022060109133260000_ref21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12072-008-9052-7","article-title":"Prognostic analysis of pulmonary metastases from hepatocellular carcinoma","volume":"2","author":"Zhang","year":"2008","journal-title":"Hepatol Int"},{"key":"2022060109133260000_ref22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1159\/000510798","article-title":"Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC trial","volume":"9","author":"Sch\u00fctte","year":"2020","journal-title":"Liver Cancer"},{"key":"2022060109133260000_ref23","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/j.ijrobp.2011.09.053","article-title":"Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma","volume":"82","author":"Bae","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022060109133260000_ref24","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/jgh.12249","article-title":"Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma","volume":"28","author":"Park","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"2022060109133260000_ref25","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/0360-3016(83)90426-1","article-title":"Hypofractionated radiotherapy for the palliation of advanced pelvic malignancy","volume":"9","author":"Hodson","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022060109133260000_ref26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3748\/wjg.v21.i1.94","article-title":"Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma","volume":"21","author":"Kondo","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2022060109133260000_ref27","doi-asserted-by":"crossref","first-page":"48586","DOI":"10.18632\/oncotarget.9374","article-title":"Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"2022060109133260000_ref28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JTO.0b013e3181cbf622","article-title":"Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer","volume":"5","author":"Kim","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2022060109133260000_ref29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ijrobp.2008.08.034","article-title":"Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases","volume":"74","author":"Jang","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022060109133260000_ref30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.prro.2012.08.006","article-title":"Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease","volume":"3","author":"Corbin","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"2022060109133260000_ref31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/1748-717X-7-222","article-title":"Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using tomotherapy","volume":"7","author":"Chang","year":"2012","journal-title":"Radiat Oncol"},{"key":"2022060109133260000_ref32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2018.12.049","article-title":"Predictive factors for response and survival in a cohort of oligometastatic patients treated with stereotactic body radiation therapy","volume":"104","author":"Franceschini","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022060109133260000_ref33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2169\/internalmedicine.9826-17","article-title":"The safety and efficacy of combination therapy of sorafenib and radiotherapy for advanced hepatocellular carcinoma: a retrospective study","volume":"57","author":"Wada","year":"2018","journal-title":"Intern Med"},{"key":"2022060109133260000_ref34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3857\/roj.2021.00276","article-title":"Tailored stereotactic radiotherapy technique using deep inspiration breath-hold to reduce stomach dose for cardiac radioablation","volume":"39","author":"Cha","year":"2021","journal-title":"Radiat Oncol J"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/6\/616\/43900463\/hyac028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/6\/616\/43900463\/hyac028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T09:14:23Z","timestamp":1654074863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/52\/6\/616\/6551107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,21]]},"published-print":{"date-parts":[[2022,5,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac028","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,3,21]]}}}